Abstract:Breast cancer is the most commonly diagnosed cancer in women globally (1). The estimated numbers of breast cancer cases account for 32% of all new diagnoses for women in the United States in 2024 (2). Radiotherapy is an important component of breast cancer therapy. Adjuvant radiotherapy is the standard of care for patients receiving breast-conserving surgery, which can significantly reduce locoregional recurrence and the breast cancer death rate (3). Regional node radiotherapy in early breast cancer patients significantly reduced breast cancer mortality and all-cause mortality in trials done in recent years (4). However, the development of radioresistance remains a major challenge in improving outcomes for breast cancer patients who receive radiotherapy (5). This research topic aims to explore the mechanisms of radioresistance and find promising predictive and therapeutic methods for radioresistant breast cancer patients. 8 articles were accepted. Screening of radioresistant breast cancer patients is important for improving the effect of radiotherapy. In this topic, Zhang et al. proposed a novel radiotherapy response classification system based upon molecular profiles for estimating radiosensitivity for individual breast cancer patients and elucidated a methodological advancement for the synergy of radiotherapy with immune checkpoint blockade (ICB). This study classified breast cancer patients to radiotherapy-sensitive and radiotherapy-resistant clusters by quantitative RT-PCR analyses of differentially expressed radiotherapy response-related genes (DERRGs). Then, the Riskscore was proposed to improve patient prognosis. The high Riskscore samples had lower radiotherapeutic response and stronger DNA damage repair as well as poor anticancer immunity. Zheng et al. found that a higher Nottingham prognostic index (NPI) score is an independent risk factor for predicting locoregional recurrence in breast cancer. Two nomogram prediction models related to radioresistance were constructed in this study. Six significant variables were identified for the models, including age, body mass index (BMI), TNM stage, NPI, vascular invasion, and perineural invasion. The nomogram prediction model based on the NPI has undergone internal validation and has been found to have good discrimination and calibration. The two studies highlight the importance of identifying radioresistant breast cancer patients through different clinical variables and special radiotherapy response-related genes.The de-escalation of radiotherapy for selected breast cancer patients is also important for overcoming radioresistance. Because prolonged radiation therapy is more likely to induce secondary radioresistance. Liu et al. conducted a retrospective analysis and found that omitting regional lymph node irradiation may be a safe option in T1-2N1 HER2-overexpressing by breast cancer patients receiving standardized anti-HER2 targeted therapy, particularly in ER-positive or lymph vascular invasion status (LVI)-negative subgroups. The strategies of de-escalated radiotherapy in target volume are also researched for breast cancer patients. The European Society for Radiotherapy and Oncology–Advisory Committee in Radiation Oncology Practice (ESTRO-ACROP) updated a new target volume delineation guideline for postmastectomy radiotherapy after implant-based reconstruction. Park et al. aimed to evaluate the impact on breast complications with the new guideline compared to the conventional guidelines, and found that the new ESTRO-ACROP target volume guideline did not demonstrate significant differences in major or any breast complications compared to the conventional guidelines. It showed a tendency to reduce complication risks by the volume de-escalation of radiotherapy.Tumor volume and radiation dose are predictors of response and can be used to guide the decision-making for patients with radioresistant brain metastases (6). Stereotactic radiosurgery offers a benefit over whole-brain radiation, which is attributed to the reduction of radioresistance and neurotoxicity (7). Li et al. conducted a retrospective analysis to study the role of brain radiotherapy in HER2-positive breast cancer with brain metastases. Because it is considered that with the development of HER2-targeted therapies, brain radiotherapy can be delayed, and stereotactic radiosurgery (SRS) can be used in more patients. The authors concluded that HER2-positive breast cancer with brain metastases still faces significant challenges, particularly those with high intracranial tumor burden, which correlates with poorer outcomes and higher incidence of leptomeningeal metastasis. Larger tumors necessitated more comprehensive treatment approaches, such as whole-brain radiation therapy (WBRT) and SRS. And the target tumor volume and dose of intraoperative radiotherapy (IORT) are also much smaller than conventional radiation. Bhimani et al. demonstrate the suc -Abstract Truncated-

Palliative Radiotherapy for Symptomatic Primary Tumors in Patients With Locally Advanced Breast Cancer

Palliative beam radiotherapy offered real-world survival benefit to metastatic rectal cancer: A large US population-based and propensity score-matched study.

Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer

Palliative Thoracic Radiotherapy in the Era of Modern Cancer Care for NSCLC

Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast Cancer

Editorial: Radioresistance in breast cancer

Intensity Modulated Radiotherapy and Volumetric Modulated Arc Therapy in the Treatment of Breast Cancer: An Updated Review

Molecular Changes in Breast Cancer Induced by Radiation Therapy

A 15-Year Single-Institution Retrospective Study of Primary Pancreatic Cancer Treated with Non-Ablative Palliative Radiotherapy

Clinical trials that will change practices: News in palliative radiotherapy

Challenges in the combination of radiotherapy and immunotherapy for breast cancer

Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives

Radiotherapeutic Management and Prognostic Factors for Patients with Bone Metastases of Postoperative Breast Cancer

Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.

Palliative pelvic radiotherapy for symptomatic frail or metastatic patients with rectal adenocarcinoma: A systematic review

Immunotherapy and Radiation therapy Sequencing in Breast Cancer: A Systematic Review

Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data

Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy